EN DE
Watch Oneness Biotech Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Oneness Biotech Co Ltd (4743) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Oneness Biotech Co Ltd stock TWD 9.92, price TWD 44.95, that is 77.9% below the price, quality 41 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0004743000

OB Oneness Biotech Co Ltd logo Thin data Nov 6, 2026

Oneness Biotech Co Ltd

4743 · TWO
Very expensive, weak quality

Our calculation puts a fair price 78% below what the stock costs today.

Highly profitable · 39.6% net margin (TTM)
Revenue last quarter +50% vs. a year ago.
Quality 41/100
Expensive Growth (revenue YoY +9.5 %/yr in TWD)
Mixed vs. peers (4/8)
Fair value 9.92 TWD · Strongly overvalued (−77.9%)
Negative free cash flow
Narrow moat 32/100
Thin data
Watch Oneness Biotech Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

286.83 TWD 41.75 TWD Fair Value 9.92 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range 41.75 TWD – 286.83 TWD · fair‑value band 6.55 TWD – 12.40 TWD · the 44.95 TWD price screens above the 9.92 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.

Follow Oneness Biotech Co in your weekly email

Every Wednesday you see whether Oneness Biotech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation and Organic Food segments.

Show moreShow less

The company offers Fespixon which is a treatment of diabetic foot ulcer; and Bonvadis, a wound care medical device.

It also develops FB825, which is in Phase II clinical trial for treating atopic dermatitis and allergic asthma; FB704A which is in Phase II clinical trial for the treatment of rheumatoid arthritis and inhibiting tumor angiogenesis; SNS812, which is in Phase II clinical trial for the treatment of COVID; and SNS851 which is in clinical development for potential applications in metabolic diseases such as obesity, diabetes, hypercholesterolemia, and fatty liver disease.

In addition, the company is involved in the management of agriculture cultivation and organic food trading business; and sale of organic food, dietary supplements, and beverages. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.

Stock analysis

Oneness Biotech Co Ltd (4743) currently trades at 44.95 TWD, while our model-based Fair Value estimate is 9.92 TWD, 78% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 93/100, which puts the data coverage at low.

Scenario range: 6.55 TWD (bear) to 12.40 TWD (bull), the price of 44.95 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Oneness Biotech Co Ltd reported revenue of 129M TWD in FY2025 versus 65.8M TWD in FY2021, a compound +18.4%/yr. Reported net income was −1.0B TWD in FY2025.

Key figures

Market cap 21.5B TWD (≈ $657M) Small · P/E ratio 345.8 · EPS (TTM) 0.1300 TWD · Net margin 39.6% · Return on equity 0.6% · Return on assets (EBIT) −4.3% (5-year average) · Operating margin −515% · Revenue (TTM) 154M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 40% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −78%, 4743 screens richer than that median.

Fair Value models

Bear 6.55 TWD Fair Value 9.92 TWD Bull 12.40 TWD
Price 44.95 TWD · Downside -77.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.1111 TWD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 6.55 TWD 9.92 TWD 12.40 TWD 52
All 1 models by family
Asset-Based
NCAV (Graham) 6.55 TWD 9.92 TWD 12.40 TWD 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 49
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 87
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 57
How calm the share price moves, does not count
Price momentum 29
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 69
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 47/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−588.3% (2020) → −618.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

4743 screens overvalued: fair value 78% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Oneness Biotech Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 41 · Below median
Fair Value upside −77.9% · Bottom 25%
Profitability
Return on equity (12 months) 0.6% · Above median
Return on assets −8.9% · Above median
Net margin (12 months) 39.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 49.8% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 345.8× · Priciest 25%
P/B 2.08× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)2 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 4743
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 4743
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs 4743
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 4743
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 4743
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs 4743
argenx SE ARGX $927.21 $908.40 −2% vs 4743
CSL Limited CSL A$202.04 A$183.04 −9% vs 4743
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 4743
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 4743

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Oneness Biotech Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Oneness Biotech Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/4743

Frequently asked questions

Is Oneness Biotech Co Ltd (4743) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 9.92 TWD versus a price of 44.95 TWD, about 78% lower (overvalued).
What is the fair value of 4743?
Our model-based fair value for Oneness Biotech Co Ltd is 9.92 TWD (as of Nov 6, 2026), built from audited fundamentals. The current price: 44.95 TWD.
What is the quality score of 4743?
Oneness Biotech Co Ltd has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oneness Biotech Co Ltd (4743)?
Our model-based price target is the fair value of 9.92 TWD (as of Nov 6, 2026) from 1 valuation models. Cautious scenario 6.55 TWD, optimistic scenario 12.40 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Oneness Biotech Co Ltd stock forecast for 2026?
Our models put fair value at 9.92 TWD, about 78% lower versus a price of 44.95 TWD (overvalued). Cautious scenario 6.55 TWD, optimistic scenario 12.40 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Oneness Biotech Co Ltd (4743)?
Oneness Biotech Co Ltd reported trailing-twelve-month revenue of about 154M TWD (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Oneness Biotech Co Ltd (4743)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oneness Biotech Co Ltd it is 9.92 TWD per share (as of Nov 6, 2026), against a price of 44.95 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Oneness Biotech Co Ltd stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 4743 trades above its calculated fair value: price 44.95 TWD, fair value 9.92 TWD, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4743?
No. The price is what the market pays today (44.95 TWD); the fair value is what the company's own numbers justify (9.92 TWD). For Oneness Biotech Co Ltd the two are 35.03 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Oneness Biotech Co Ltd worth?
The market values Oneness Biotech Co Ltd at about 21.5B TWD (market capitalisation, as of Nov 6, 2026). Per share that is 44.95 TWD; our models calculate a fair value of 9.92 TWD per share.
What do the bullish and bearish scenarios say about 4743?
Our models span a range for Oneness Biotech Co Ltd: cautious scenario 6.55 TWD, base 9.92 TWD, optimistic 12.40 TWD per share (as of Nov 6, 2026, price 44.95 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4743?
Oneness Biotech Co Ltd trades at a price-to-earnings ratio of 345.8 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 9.92 TWD is built from several models across several years. Other multiples: P/B 2.1.
How solid is the balance sheet of Oneness Biotech Co Ltd (4743)?
Balance-sheet figures for Oneness Biotech Co Ltd (as of Nov 6, 2026): return on equity 0.6%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 4743 from its 52-week high?
Oneness Biotech Co Ltd trades at 44.95 TWD, about 40% below its 52-week high of 74.80 TWD and 8% above the low of 41.75 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 9.92 TWD is for.
Which stocks are comparable to Oneness Biotech Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oneness Biotech Co Ltd stock attractive at the current price?
The data as of Nov 6, 2026: price 44.95 TWD, calculated fair value 9.92 TWD (−78%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4743 calculated?
We run Oneness Biotech Co Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 9.92 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Oneness Biotech Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oneness Biotech Co Ltd (4743)?
The closing price on Nov 6, 2026 was 44.95 TWD. Our model-based fair value is 9.92 TWD, about 78% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oneness Biotech Co Ltd right now?
The price sits above even our optimistic bull case (12.40 TWD). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (6.55 TWD to 12.40 TWD) leaves room in how you read the outcome.

Key figures of Oneness Biotech Co Ltd

How large is the market capitalisation of Oneness Biotech Co Ltd (4743)?
The market capitalisation of Oneness Biotech Co Ltd is 21.5B TWD (≈ $657M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Oneness Biotech Co Ltd (4743)?
Earnings per share at Oneness Biotech Co Ltd are 0.1300 TWD (price ÷ EPS = P/E 345.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Oneness Biotech Co Ltd (4743)?
The net margin of Oneness Biotech Co Ltd is 39.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oneness Biotech Co Ltd (4743)?
The return on equity (ROE) of Oneness Biotech Co Ltd is 0.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oneness Biotech Co Ltd (4743)?
On an EBIT basis the return on assets of Oneness Biotech Co Ltd is −4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oneness Biotech Co Ltd (4743)?
The operating margin of Oneness Biotech Co Ltd is −515% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oneness Biotech Co Ltd (4743)?
Revenue at Oneness Biotech Co Ltd is growing +49.8% versus a year earlier (3y avg −50.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Oneness Biotech Co Ltd (4743)?
Earnings per share at Oneness Biotech Co Ltd are growing +219% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Oneness Biotech Co Ltd (4743) generate?
The free cash flow of Oneness Biotech Co Ltd is −487M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Oneness Biotech Co Ltd (4743) hold?
Oneness Biotech Co Ltd holds more cash than debt, 381M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Oneness Biotech Co Ltd in the live analysis

One click puts Oneness Biotech Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.